The Emergence of Neoadjuvant Therapy in Advanced Melanoma

Overview

Journal Melanoma Manag

Date 2019 Dec 7

PMID 31807278

Citations 7

Authors

James Sun

Dennis A Kirichenko

Jonathan S Zager

Zeynep Eroglu

Affiliations

Soon will be listed here.

Abstract

The discovery of immunotherapy and targeted therapy has introduced new and effective treatment options for advanced melanoma, providing therapeutic options where none existed before. The natural extension of these novel therapies is to identify their role in the neoadjuvant setting. Neoadjuvant therapy for advanced melanoma is still in its infancy, with a wealth of clinical trials underway. Early results are promising, allowing for management of a disease that previously had few options. We review the current literature and interim results from several ongoing investigations to understand the current state of neoadjuvant treatment options and what is to come. These studies pave the way for further advancements in melanoma therapy.

Citing Articles

Clinical Approaches for the Management of Skin Cancer: A Review of Current Progress in Diagnosis, Treatment, and Prognosis for Patients with Melanoma.

Connor C, Carr Q, Sweazy A, McMasters K, Hao H Cancers (Basel). 2025; 17(4).

PMID: 40002300 PMC: 11853469. DOI: 10.3390/cancers17040707.

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.

Najjar Y, McCurry D, Lin H, Lin Y, Zang Y, Davar D Clin Cancer Res. 2021; 27(15):4195-4204.

PMID: 33753453 PMC: 8338751. DOI: 10.1158/1078-0432.CCR-20-4301.

Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data.

Zhang X, Liang Y Biomed Res Int. 2021; 2021:8197936.

PMID: 33506034 PMC: 7815395. DOI: 10.1155/2021/8197936.

Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma.

Ceci C, Atzori M, Lacal P, Graziani G Cancers (Basel). 2020; 12(11).

PMID: 33212945 PMC: 7698460. DOI: 10.3390/cancers12113401.

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic or -Mutated Melanoma Patients.

Herbreteau G, Vallee A, Knol A, Theoleyre S, Quereux G, Frenard C Cancers (Basel). 2020; 12(7).

PMID: 32664549 PMC: 7409003. DOI: 10.3390/cancers12071871.

References

Liu B, Robinson M, Han Z, Branston R, English C, Reay P . ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10(4):292-303. DOI: 10.1038/sj.gt.3301885. View

Tetzlaff M, Messina J, Stein J, Xu X, Amaria R, Blank C . Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018; 29(8):1861-1868. PMC: 6096739. DOI: 10.1093/annonc/mdy226. View

Kaufman H, Bines S . OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010; 6(6):941-9. DOI: 10.2217/fon.10.66. View

Fadaki N, Cardona-Huerta S, Martineau L, Thummala S, Cheng S, Bunker S . Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep. 2012; 2012. PMC: 4544316. DOI: 10.1136/bcr-2012-007034. View

Sloot S, Zager J, Kudchadkar R, Messina J, Benedict J, Gonzalez R . BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res. 2016; 26(1):83-7. DOI: 10.1097/CMR.0000000000000214. View

Gorantla V, Kirkwood J . State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am. 2014; 28(3):415-35. PMC: 4040458. DOI: 10.1016/j.hoc.2014.02.010. View

Zippel D, Markel G, Shapira-Frommer R, Ben-Betzalel G, Goitein D, Ben-Ami E . Perioperative BRAF inhibitors in locally advanced stage III melanoma. J Surg Oncol. 2017; 116(7):856-861. DOI: 10.1002/jso.24744. View

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M . Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. J Clin Oncol. 2018; 36(35):3441-3449. PMC: 6286159. DOI: 10.1200/JCO.18.01219. View

Pretto F, Elia G, Castioni N, Neri D . Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother. 2014; 63(9):901-10. PMC: 11029048. DOI: 10.1007/s00262-014-1562-7. View

10.

Legha S, Ring S, Bedikian A, Plager C, Eton O, Buzaid A . Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996; 7(8):827-35. DOI: 10.1093/oxfordjournals.annonc.a010762. View

11.

Blank C, Rozeman E, Fanchi L, Sikorska K, van de Wiel B, Kvistborg P . Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018; 24(11):1655-1661. DOI: 10.1038/s41591-018-0198-0. View

12.

Liu J, Blake S, Yong M, Harjunpaa H, Ngiow S, Takeda K . Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016; 6(12):1382-1399. DOI: 10.1158/2159-8290.CD-16-0577. View

13.

Weide B, Derhovanessian E, Pflugfelder A, Eigentler T, Radny P, Zelba H . High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer. 2010; 116(17):4139-46. DOI: 10.1002/cncr.25156. View

14.

Koers K, Francken A, Haanen J, Woerdeman L, van der Hage J . Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. J Clin Oncol. 2013; 31(16):e251-3. DOI: 10.1200/JCO.2012.45.3845. View

15.

Amaria R, Prieto P, Tetzlaff M, Reuben A, Andrews M, Ross M . Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018; 19(2):181-193. DOI: 10.1016/S1470-2045(18)30015-9. View

16.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

17.

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View

18.

Harrington K, Andtbacka R, Collichio F, Downey G, Chen L, Szabo Z . Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther. 2016; 9:7081-7093. PMC: 5119624. DOI: 10.2147/OTT.S115245. View

19.

Legha S, Ring S, Eton O, Bedikian A, Buzaid A, Plager C . Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998; 16(5):1752-9. DOI: 10.1200/JCO.1998.16.5.1752. View

20.

Serrone L, Zeuli M, Sega F, Cognetti F . Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000; 19(1):21-34. View